Surgalign Holdings Inc (NASDAQ:SRGA) announced the publication of results from EVoluSIon (EVSI) study of clinical outcomes following minimally invasive sacroiliac joint (SIJ) fusion with decortication.
- The EVoluSIon Clinical Study reports 12-month clinical outcomes following minimally invasive SIJ fusion using the SImmetry Sacroiliac Joint Fusion system to treat SIJ dysfunction.
- The study included 250 patients.
- The results demonstrated statistically significant improvements in both pain and disability and a statistically significant reduction in the number of patients using opioids.
- Also See: Surgalign Shares Tank After $20 Equity Capital Raise.
- Specifically, 72.2% of patients achieved a reduction in pain, 62.5% of patients achieved a reduction in disability.
- 57.1% of patients reported (N=201) cessation of opioid use, and 68.7% achieved radiographic fusion.
- The SIJ has been reported to be the source of pain in approximately 18-30% of patients presenting with chronic low back pain and increases to more than 40% in patients with prior lumbar fusion.
- Price Action: SRGA shares are up 1.09% at $0.34 during the market session on the last check Thursday.
